Protein may predict chemotherapy response in osteosarcoma

Share this article:

The expression of the P16 protein, which inhibits cell growth, may be a useful biomarker for predicting how osteosarcoma will respond to standard chemotherapy, researchers concluded after finding that P16 expression significantly correlates with chemotherapy response among patients with that form of cancer.

As a team led by Dariusz Borys of the University of California–Davis Department of Pathology and Laboratory Medicine in Sacramento explained in Human Pathology, pathologic response to neoadjuvant chemotherapy is highly correlated with survival among persons with osteosarcoma, the most common bone cancer in children. (Osteosarcoma can also affect people after age 60 years.) However, there are no established molecular markers to predict response to this treatment.

The research group analyzed data from pretreatment biopsy specimens of 40 patients with osteosarcoma. The median age of the patients was 15 years (range, 9 to 75 years), and 35% of the biopsied tumors were located in the femur. P16 expression was found to be present in 62% of the specimens.

Following chemotherapy, during surgery to remove the tumor, specimens were again collected and analyzed. Median tumor necrosis was 90%, and 55% of patients experienced “good” chemotherapy response, defined as tumor necrosis of at least 90%. These patients were significantly more likely to have had tumors that expressed the P16 protein.

After the researchers controlled for patient age and gender and for tumor subtype and location, P16 expression was independently associated with chemotherapy response.

.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Presence of uterine cancers examined among women at the time of hysterectomy ...

Among women undergoing a minimally invasive hysterectomy using electric power morcellation, uterine cancers were present in 27 per 10,000 women at the time of the procedure, according to a new study.

New approach identifies cancer mutations as targets of effective melanoma immunotherapy

A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy.

No change seen in breast cancer detection despite increased Medicare costs for ...

Breast cancer screening costs for Medicare patients skyrocketed between 2001 and 2009, but the increase did not lead to earlier detection of new breast cancer cases, according to a study.